TY - JOUR
T1 - Endothelin-1 and NO2/NO3 circulating levels after short-term (1h) oxygen supplementation in patients with chronic respiratory failure during long-term oxygen treatment (LTOT)
AU - Biondi, R.
AU - Paolocci, N.
AU - Spaccapanico, R.
AU - Bettini, M.
AU - Cantalupo, T.
AU - Brugnami, G.
AU - Capodicasa, E.
PY - 1998
Y1 - 1998
N2 - The effect of acute oxygen administration on endothelin-1 (ET-1) and nitrates (NO-/2/NO-/3), the latter as stable end products of nitric oxide (NO), were evaluated in arterial and venous blood of chronic respiratory failure (CRF) patients underwent to a continuous long-term oxygen therapy (LTOT). After one hour of oxygen supplementation, ET-1 showed a marked and significant decrease more pronounced in venous blood whereas no statistical change in NO-/2/NO-/3 concentrations were observed in both arterial and venous blood. There are evidences for increased expression of ET-1 in several pulmonary diseases and for ET-1 plasma reduction in Adult Respiratory Distress Syndrome (ARDS) in patients which recovered. ET-1 is a potent human pulmonary vessel constrictor and may have other effects including plasma exudation, increased mucus secretion and a increased fibrinogenesis. Our data suggest that the improvement in air function, evaluated in part by the decreased release of inflammatory mediators and mainly by reduction in the pulmonary arterial resistence, may be a consequence of the decrease in ET-1 content in the lungs of CRF patients treated with LTOT.
AB - The effect of acute oxygen administration on endothelin-1 (ET-1) and nitrates (NO-/2/NO-/3), the latter as stable end products of nitric oxide (NO), were evaluated in arterial and venous blood of chronic respiratory failure (CRF) patients underwent to a continuous long-term oxygen therapy (LTOT). After one hour of oxygen supplementation, ET-1 showed a marked and significant decrease more pronounced in venous blood whereas no statistical change in NO-/2/NO-/3 concentrations were observed in both arterial and venous blood. There are evidences for increased expression of ET-1 in several pulmonary diseases and for ET-1 plasma reduction in Adult Respiratory Distress Syndrome (ARDS) in patients which recovered. ET-1 is a potent human pulmonary vessel constrictor and may have other effects including plasma exudation, increased mucus secretion and a increased fibrinogenesis. Our data suggest that the improvement in air function, evaluated in part by the decreased release of inflammatory mediators and mainly by reduction in the pulmonary arterial resistence, may be a consequence of the decrease in ET-1 content in the lungs of CRF patients treated with LTOT.
UR - http://www.scopus.com/inward/record.url?scp=0031595930&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031595930&partnerID=8YFLogxK
U2 - 10.3109/08923979809034825
DO - 10.3109/08923979809034825
M3 - Article
C2 - 9736447
AN - SCOPUS:0031595930
SN - 0892-3973
VL - 20
SP - 433
EP - 446
JO - Immunopharmacology and Immunotoxicology
JF - Immunopharmacology and Immunotoxicology
IS - 3
ER -